{
  "meta": {
    "title": "54_Multiple_Sclerosis",
    "url": "https://brainandscalpel.vercel.app/54-multiple-sclerosis-23cc273a.html",
    "scrapedAt": "2025-11-30T06:57:25.053Z"
  },
  "questions": [
    {
      "id": 91276,
      "choices": [
        {
          "id": 206362,
          "text": "Mycophenolate mofetil"
        },
        {
          "id": 206363,
          "text": "Mitoxantrone"
        },
        {
          "id": 206364,
          "text": "Teriflunomide"
        },
        {
          "id": 206365,
          "text": "Alemtuzumab"
        }
      ],
      "text": "All of the following drugs are approved for Relapsing Remitting Multiple sclerosis Except",
      "unique_key": "Q1280067",
      "question_audio": null,
      "question_video": null,
      "map_id": 34846061,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Mycophenolate mofetil. Mycophenolate mofetil is not approved for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). It is an immunosuppressive agent primarily used in the prevention of organ transplant rejection and in the treatment of autoimmune diseases such as lupus nephritis. While it has been investigated in clinical trials for MS, it has not received approval for the treatment of RRMS. It works by inhibiting lymphocyte proliferation, but its use in MS is not established or recommended for relapsing forms of multiple sclerosis. Incorrect Answers: B. Mitoxantrone: Mitoxantrone is a chemotherapeutic agent that has been approved for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS), especially in patients who do not respond to other therapies. It works by suppressing the immune system and reducing inflammation, thereby reducing relapses and disease progression. Though it is not used as a first-line treatment due to its potential side effects, it is still approved for MS treatment. C. Teriflunomide: Teriflunomide is an approved oral disease-modifying therapy for Relapsing Remitting Multiple Sclerosis (RRMS). It works by inhibiting the pyrimidine synthesis pathway, which leads to reduction in lymphocyte proliferation and a decrease in inflammatory activity. It is an FDA-approved drug for RRMS, shown to reduce relapses and delay disease progression. D. Alemtuzumab: Alemtuzumab is an FDA-approved monoclonal antibody used in the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). It works by targeting CD52 on the surface of T and B lymphocytes, leading to their depletion and subsequent modulation of the immune system. It has shown effectiveness in reducing relapses and slowing disability progression in patients with RRMS. Thus, it is an approved treatment for RRMS.",
      "correct_choice_id": 206362,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38482711701703448/38482711701703448.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/38482711701703448/38482711701703448.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91277,
      "choices": [
        {
          "id": 206366,
          "text": "Loss of Schwann cells in peripheral neurons"
        },
        {
          "id": 206367,
          "text": "An overall loss of dopaminergic release throughout the brain and spinal cord"
        },
        {
          "id": 206368,
          "text": "Loss of peripheral cholinergic neurons"
        },
        {
          "id": 206369,
          "text": "Demyelination of CNS neurons"
        }
      ],
      "text": "A young woman in her early twenties experiences loss of sensation in her legs and weakness in her limbs. A neurological examination indicates some spasticity of the limbs as well . the neurologist examination indicates some spasticity of the limbs as well . The neurologist makes a preliminary diagnosis of early multiple sclerosis (MS) . Assuming that this diagnosis is correct, which of the following best accounts for the diminution of sensory and motor functions?",
      "unique_key": "Q6220155",
      "question_audio": null,
      "question_video": null,
      "map_id": 34541873,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Demyelination of CNS neurons. In Multiple Sclerosis (MS), the primary pathological feature is the demyelination of neurons in the central nervous system (CNS), which includes the brain and spinal cord. Demyelination occurs due to an autoimmune attack on the myelin sheath, which is the protective covering around the nerve fibers. The loss of myelin disrupts the normal transmission of electrical signals between neurons, leading to the sensory and motor dysfunction observed in MS. This demyelination causes symptoms such as loss of sensation, weakness, spasticity, and other neurological impairments, as seen in the patient described in the question. Incorrect Answers: A. Loss of Schwann cells in peripheral neurons: Schwann cells are responsible for the myelination of peripheral nervous system (PNS) neurons. While Schwann cell dysfunction can lead to peripheral neuropathies, it is not the cause of multiple sclerosis, which primarily involves CNS neurons. In MS, the demyelination occurs in the brain and spinal cord, not the peripheral nerves. Therefore, loss of Schwann cells is not responsible for the symptoms in MS. B. An overall loss of dopaminergic release throughout the brain and spinal cord: This description is more characteristic of Parkinson’s disease, where there is degeneration of dopaminergic neurons in the substantia nigra of the brain. In Parkinson’s disease, the loss of dopamine leads to motor symptoms such as bradykinesia, tremor, and rigidity. In Multiple Sclerosis, the primary issue is demyelination, not the loss of dopamine. Therefore, the loss of dopaminergic release does not account for the sensory and motor dysfunction in MS. C. Loss of peripheral cholinergic neurons: Cholinergic neurons are involved in the autonomic nervous system and muscle function, particularly in the peripheral nervous system. While dysfunction of cholinergic pathways can contribute to conditions like dementia or neurodegenerative diseases, it is not the underlying cause of Multiple Sclerosis. In MS, the issue lies in the demyelination of CNS neurons, not the loss of cholinergic neurons.",
      "correct_choice_id": 206369,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50498901701703473/50498901701703473.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/50498901701703473/50498901701703473.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91278,
      "choices": [
        {
          "id": 206370,
          "text": "Optic neuritis"
        },
        {
          "id": 206371,
          "text": "Asymmetric involvement of abducens nerve"
        },
        {
          "id": 206372,
          "text": "Asymmetric involvement of oculomotor nerve"
        },
        {
          "id": 206373,
          "text": "Internuclear ophthalmoplegia"
        }
      ],
      "text": "Diplopia in multiple sclerosis is due to",
      "unique_key": "Q4587055",
      "question_audio": null,
      "question_video": null,
      "map_id": 34619442,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Internuclear ophthalmoplegia. Diplopia (double vision) in Multiple Sclerosis (MS) is most commonly due to internuclear ophthalmoplegia (INO). INO occurs when there is demyelination of the medial longitudinal fasciculus (MLF), a structure that coordinates eye movements between the two eyes. The MLF allows for the coordinated movement of both eyes in the horizontal direction. In MS, demyelination of the MLF can impair the ability of the eyes to move together in one direction, leading to asymmetric eye movements. This results in diplopia, especially when attempting to gaze to the side. Therefore, INO is a hallmark cause of diplopia in MS patients. Incorrect Answers: A. Optic neuritis: Optic neuritis is a condition where inflammation of the optic nerve causes visual disturbances, typically in the form of blurred vision or vision loss in one eye. While optic neuritis is common in MS and affects vision, it does not typically cause diplopia, as it involves the visual pathway rather than the eye movement pathways. Diplopia is more associated with problems in the coordination of eye movements, such as in internuclear ophthalmoplegia. B. Asymmetric involvement of abducens nerve: The abducens nerve controls the lateral rectus muscle, which is responsible for abducting the eye (moving it outward). While abducens nerve palsy can cause diplopia, it is less common in MS compared to internuclear ophthalmoplegia. MS-related diplopia is usually caused by demyelination in the MLF, which affects coordination between both eyes, rather than isolated involvement of the abducens nerve. C. Asymmetric involvement of oculomotor nerve: The oculomotor nerve controls most of the movements of the eye, including upward, downward, and inward movements, as well as pupillary constriction. Although asymmetric involvement of the oculomotor nerve can cause eye movement abnormalities, it is not the most common cause of diplopia in MS. Diplopia in MS is more often the result of internuclear ophthalmoplegia caused by demyelination of the MLF, affecting coordination of the eye movements rather than isolated damage to the oculomotor nerve.",
      "correct_choice_id": 206373,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34366531701703487/34366531701703487.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34366531701703487/34366531701703487.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91279,
      "choices": [
        {
          "id": 206374,
          "text": "Relapsing multiple sclerosis"
        },
        {
          "id": 206375,
          "text": "Secondary progressive multiple sclerosis"
        },
        {
          "id": 206376,
          "text": "Primary progressive multiple sclerosis"
        },
        {
          "id": 206377,
          "text": "Progressive relapsing multiple sclerosis"
        }
      ],
      "text": "Most common type of multiple sclerosis is",
      "unique_key": "Q6418661",
      "question_audio": null,
      "question_video": null,
      "map_id": 34148114,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Relapsing multiple sclerosis. Relapsing-remitting multiple sclerosis (RRMS) is the most common type of multiple sclerosis (MS), accounting for about 85-90% of cases at the time of diagnosis. In this form, patients experience episodes of worsening neurological function (relapses) followed by periods of partial or complete recovery (remissions). These relapses are typically due to acute inflammation and demyelination in the central nervous system (CNS). RRMS is characterized by the initial relapsing course, but over time, some individuals may transition to other forms of MS, such as secondary progressive MS. Incorrect Answers: B. Secondary progressive multiple sclerosis: Secondary progressive multiple sclerosis (SPMS) typically evolves from relapsing-remitting MS (RRMS) after a number of years, in which the relapses become less frequent and disability gradually worsens. SPMS is characterized by a steady progression of symptoms without clear remissions. Although SPMS is common in the later stages of MS, it is not the most common initial form of MS. C. Primary progressive multiple sclerosis: Primary progressive multiple sclerosis (PPMS) is a less common form of MS, accounting for about 10-15% of cases. In PPMS, patients experience a gradual worsening of neurological function from the onset, without clear relapses or remissions. This form is usually associated with a slower progression of disability and a more severe disease course compared to RRMS. D. Progressive relapsing multiple sclerosis: Progressive relapsing multiple sclerosis (PRMS) is the rarest form of MS, characterized by a progressive worsening of symptoms from the outset, with occasional relapses. It is a more severe form of MS and is much less common than RRMS. PRMS is not the most common type and typically affects a small subset of individuals with MS.",
      "correct_choice_id": 206374,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/59661521701703497/59661521701703497.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/59661521701703497/59661521701703497.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91280,
      "choices": [
        {
          "id": 206378,
          "text": "Relapsing-Remitting multiple sclerosis"
        },
        {
          "id": 206379,
          "text": "Primary Progressive multiple sclerosis"
        },
        {
          "id": 206380,
          "text": "Secondary progressive multiple sclerosis"
        },
        {
          "id": 206381,
          "text": "None of the above"
        }
      ],
      "text": "Identify the type of multiple sclerosis?<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/course_file_meta/6565757Capture.JPG\" alt=\"Question Image\"></p>",
      "unique_key": "Q7045809",
      "question_audio": null,
      "question_video": null,
      "map_id": 34627861,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Secondary progressive multiple sclerosis. Secondary progressive multiple sclerosis (SPMS) typically evolves from relapsing-remitting multiple sclerosis (RRMS) after a period of fluctuating relapses and remissions. Over time, the relapses decrease, and the disease becomes progressively worse, with gradual worsening of neurological function and increasing disability, often without distinct relapses. This transition from RRMS to SPMS is a common progression in the disease and marks a more chronic and steadily progressive phase of MS. Incorrect Answers: A. Relapsing-Remitting multiple sclerosis: Relapsing-remitting multiple sclerosis (RRMS) is the most common type of MS, where patients experience episodes of acute neurological worsening (relapses) followed by periods of partial or complete recovery (remissions). This is the initial form of MS in most patients, but it does not account for the long-term progression after multiple relapses, which can eventually evolve into secondary progressive MS. Since the question is asking for a type of MS that has already progressed, RRMS would not be the correct answer. B. Primary Progressive multiple sclerosis: Primary progressive multiple sclerosis (PPMS) is a form of MS where symptoms gradually worsen from the onset, with no clear periods of relapse or remission. PPMS is much less common than RRMS and typically leads to a gradual decline in function without remissions. This is not the case in the scenario where the patient progresses from an initial relapsing phase, which is more characteristic of SPMS. D. None of the above: Since secondary progressive multiple sclerosis (SPMS) is the correct diagnosis based on the scenario described, the option \"None of the above\" is incorrect. SPMS is a well-established type of MS, and this choice would not apply. In summary, secondary progressive multiple sclerosis (SPMS) is the correct answer because it represents the transition from relapsing-remitting MS to a phase of gradual and continuous progression without clear relapses.",
      "correct_choice_id": 206380,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1344931701703508/1344931701703508.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1344931701703508/1344931701703508.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 91281,
      "choices": [
        {
          "id": 206382,
          "text": "A"
        },
        {
          "id": 206383,
          "text": "B"
        },
        {
          "id": 206384,
          "text": "C"
        },
        {
          "id": 206385,
          "text": "None of these"
        }
      ],
      "text": "Which of the following is secondary progressive multiple sclerosis?<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/Qid%2012409.jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q9599842",
      "question_audio": null,
      "question_video": null,
      "map_id": 34094223,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Secondary progressive multiple sclerosis (SPMS) refers to the phase of multiple sclerosis that follows an initial period of relapsing-remitting MS (RRMS). During RRMS, patients experience episodes of neurological dysfunction (relapses) followed by partial or full recovery (remissions). Over time, however, the disease may transition into secondary progressive MS, which is characterized by a gradual worsening of symptoms with or without occasional relapses. The key feature of SPMS is the steady progression of disability over time, without the clear remissions seen in the earlier relapsing phase. Incorrect Answers: A. Since the question is asking about secondary progressive MS, and option A is not described in the context of SPMS, this option is incorrect. B. Similarly, B is not indicative of secondary progressive MS. This option does not meet the criteria of secondary progressive multiple sclerosis, where a patient would have previously experienced relapsing and remitting episodes before the disease transitions into the progressive form. D. None of these: Since option C correctly describes secondary progressive multiple sclerosis, \"None of these\" is not the correct answer.",
      "correct_choice_id": 206384,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6366181701703528/6366181701703528.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6366181701703528/6366181701703528.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}